TABLE 5.
Treatment | Activity (nmol/mg of protein/min)a
|
||
---|---|---|---|
LPL | LPTA | PLB | |
Before inoculation | 1,192 ± 499 | 606 ± 202 | 18.0 ± 18.0 |
Donor LM at 6 days | 1,908 ± 356 | 690 ± 91 | 8.0 ± 4.6 |
Donor brains at 6 days | 1,801 ± 666 | 811 ± 294 | 23.7 ± 14.4 |
Donor brains at 11 days | 1,390 ± 642 | 385 ± 292 | 8.3 ± 3.7 |
Recipient brains as in 4(B) | 1,035 ± 391 | 287 ± 149 | 1.7 ± 1.6 |
Recipient brains as in 4(D) | 1,745 ± 614b | 521 ± 167 | 10.3 ± 5.5 |
The experimental protocol was the same as in Table 4. All activities are expressed as nanomoles of substrate degraded (PLB and LPL) or product formed (LPTA) mg protein−1 min−1 (means and SEM of three assays).
P = 0.04 by the paired two-tail t test compared to activity before inoculation.